721P Ipilimumab and nivolumab compassionate use program in metastatic renal cell carcinoma patients with intermediate or poor IMDC risk score: The large multicenter Italian study.
Saved in:
| Title: | 721P Ipilimumab and nivolumab compassionate use program in metastatic renal cell carcinoma patients with intermediate or poor IMDC risk score: The large multicenter Italian study. |
|---|---|
| Authors: | Basso, U.1 (AUTHOR), Paolieri, F.2 (AUTHOR), Porta, C.G.3 (AUTHOR), De Giorgi, U.4 (AUTHOR), Bracarda, S.5 (AUTHOR), Antonuzzo, L.6 (AUTHOR), Atzori, F.7 (AUTHOR), Cartenì, G.8 (AUTHOR), Procopio, G.9 (AUTHOR), Fratino, L.10 (AUTHOR), D'Arcangelo, M.11 (AUTHOR), Fornarini, G.12 (AUTHOR), Zucali, P.A.13 (AUTHOR), Cusmai, A.14 (AUTHOR), Santoni, M.15 (AUTHOR), Baldessari, C.16 (AUTHOR), Naglieri, E.17 (AUTHOR), Panni, S.18 (AUTHOR), Zagonel, V.1 (AUTHOR), Tortora, G.19 (AUTHOR) |
| Source: | Annals of Oncology. 2020 Supplement 4, Vol. 31, pS566-S566. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
